Ekaterina S. Andrienko

Ekaterina S. Andrienko

Auto-generated profile, based on publicly available information

Ekaterina S. Andrienko

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2025 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
LSLuiza R. Sakaniya
Luiza R. Sakaniya
EDEvgeniya V. Dvoriankova
Evgeniya V. Dvoriankova
ZNZofia A. Niewozinska
Zofia A. Niewozinska
KBKsenia V. Badlueva
Ksenia V. Badlueva
EAEkaterina S. Andrienko
Ekaterina S. Andrienko
НАНевозинская Зофия Анатольевна
Невозинская Зофия Анатольевна
Isotretinoin is a systemic retinoid and a vitamin A derivative. Since the 1980s, it has established itself as a highly effective treatment for severe acne. The drug acts on several pathogenesis links, reduces the size of the sebaceous glands and sebum production, and has an anti-inflammatory and immunomodulatory effect. The dosing regimen may vary, but multiple studies have shown that the best effect is achieved with 0.5–1 mg/kg daily up to a cumulative dose of 120–150 mg/kg per course. The duration of therapy is usually 8–12 months. For 15 years now, we have been using isotretinoin, manufactured using LIDOSE technology (Aknekutan), to treat moderate to severe acne. LIDOSE technology is a significant improvement of the drug, which made it possible to increase its bioavailability and reduce the food effect, which increased the compliance of therapy and reduced the number of relapses. The author’s observations showed that relapses occur several months after the end of the isotretinoin treatment course. Risk groups include patients with a history of gynecological diseases and surgical interventions. It is important to note that the disease has less pronounced clinical manifestations in case of relapse. To minimize the risk of exacerbation, women are recommended to take oral contraceptives in combination with isotretinoin after completing the course of therapy. Topical therapy is usually sufficient for patients after surgery; only in 3% of cases, a short course of isotretinoin may be required. It should be mentioned that isotretinoin therapy may be associated with side effects like dry skin and mucous membranes and, in some cases, a change in liver function tests. However, these side effects are successfully treated with moisturizers and hepatoprotectors, respectively.